<DOC>
	<DOCNO>NCT00617968</DOCNO>
	<brief_summary>Primarily evaluate rate clinical radiological response 2 group . Secondarily rate histological response .</brief_summary>
	<brief_title>GETNA2 Neoadj . TAX+Femara v Femara g I/II Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>Female patient breast cancer histologically prove microbiopsy ( 14G 16G ) enable confirmation diagnosis , evaluation histological prognostic grade , hormonal receptor HER2 status . Tumor T2 T3 , nonmetastasized , noninflammatory , unilateral Clinically radiologically measurable lesion great 2 cm ( ultrasound and/or mammogram ) Receptors RE+ and/or RP+ ( positive status determine accord criterion investigate center ) HER 2 / neu status 0 , 1+ 2+ immunohistochemistry Histological grade I II Menopausal patient age great equal 60 year Patients ECOG PS great equal 2 Satisfactory hematological , hepatic renal function : Hemoglobin great equal 10 g/dL Platelet count great equal 100x109/L Polynuclear neutrophil count great 1.5x109/L Creatinine less equal â‰¤ 1.5 ULN AST/ALT less equal 1.5 ULN Alkaline phosphatases less equal 2.5 ULN Patients able follow throughout study Patient 's consent obtain . Inflammatory T4 breast cancer T1 tumor Patients whose tumor deem doctor difficult evaluate Tumor metastatic outset ( M1 ) locally advance inoperable outset RE RP receptor negative unknown HER 2/neu positive 3 + Nonmenopausal patient Surgical biopsy and/or ganglion dissection neoadjuvant treatment Significant poorly control cardiac disorder , unstable angina pectoris , poorly control heart failure , arrhythmia require treatment , myocardial infarction within last 3 month Cardiovascular , hepatic , neurological endocrine disease , major systemic disease make difficult conduct protocol interpret result Previous history cancer occur within last 10 year , exception cervical cancer basocellular skin cancer properly treat Allergy polysorbate 80 Hypersensitivity docetaxel Participation another clinical trial one study medicinal product 30 day prior entry study Patients unable undergo medical monitoring geographical , social psychological reason</criteria>
	<gender>Female</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2009</verification_date>
</DOC>